Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells. Founded by Eric Rowinsky and Ivan Bergstein in 2003, Stemline Therapeutics is backed by investors that include Pequot Capital and is headquartered in New York.